Pluripotent Stem Cell Services
6 services found
Manufactured by:Accellta based inHaifa, ISRAEL
Process development services for culturing stem cells and or their derivatives in feeder-free, xeno-free, serum-free 3D non-adherent conditions in spinners and bioreactors. Process development services for differentiation of stem cells to the desired cell type in feeder-free, xeno-free, serum-free 3D non-adherent ...
Manufactured by:Regenerative Medical Solutions Inc. (RMS) based inMadison, WISCONSIN (USA)
RMS produces human induced pluripotent stem cell derived Islet-Like Clusters (ILC) for dual research tool and therapeutic use targeting diabetes. ILC were developed after over 15 years of research at the University of Wisconsin-Madison in the lab of world renowned researcher, Dr. ...
Manufactured by:Accellta based inHaifa, ISRAEL
Accellta developed proprietary culture systems and formulations for animal product-free and serum-free culturing of pluripotent stem cells. The systems include media that are supplemented with recombinant human growth factors and are suitable for growing hPSCs. Some of the offered medium formulations are suitable for GMP manufacturing. ...
by:Neurona Therapeutics based inSouth San Francisco, CALIFORNIA (USA)
Neurona’s clinical products are manufactured in its state-of-the-art cGMP facility in South San Francisco. Our off-the-shelf, allogeneic product candidates are derived from clinical-grade human pluripotent stem cells. We have developed proprietary methods for manufacturing pure populations of neural cell types in a stage ...
by:Neuron Experts based inMarseille, FRANCE
To keep up its high level of Competitiveness, Neuron Experts constantly develops new cellular models to provide the most accurate answers to customers’ needs: Development of new neurodegenerative disease models following current discoveries of new therapeutic targets, Development of new cellular models to study interaction between neurons and skin, Development of human Induced ...
by:Cell Manufacturing Technologies (CMaT) based inAtlanta, GEORGIA (US) (USA)
The goal of CMaT is to transform the production of cell-based therapeutics into a large-scale, low-cost, reproducible, and high-quality engineered manufacturing process for broad industry and clinical use. Specifially, three Engineered Systems (Test-Beds) are envisioned: Mesenchymal Stem/Stromal Cells (MSCs) to repair, regenerate, and restore ...